Linzagolix联合或不联合激素反向添加治疗症状性子宫肌瘤:PRIMROSE 1和2长期扩展及停药研究
PRIMROSE 1和2为随机双盲安慰剂对照3期试验,纳入1012例子宫肌瘤相关月经过多女性,评估linzagolix 100mg或200mg联合或不联合激素反向添加治疗(ABT)52周的疗效与安全性及停药后症状复发。52周时各linzagolix组MBL减少比例维持,ABT可减少骨丢失和血管舒缩症状。停药后症状较快复发。
要点
- 52周时MBL减少比例:100mg组55.0%,100mg联合ABT组86.1%,200mg组/200mg联合ABT组76.7%,200mg联合ABT组89.9%。
- 至52周最常见不良事件为潮热,其发生率至64周恢复至基线水平。
- 52周时所有组骨密度保持良好;200mg单药治疗24周后加用ABT,腰椎骨密度初始丢失至52周恢复。
核心结论
- 52周结果证实了24周观察到的治疗获益,linzagolix 100mg或200mg联合或不联合ABT可减少子宫肌瘤相关月经过多并改善生活质量,ABT使骨丢失和血管舒缩症状风险最小化。
- 每日一次linzagolix 100mg不联合ABT的部分抑制可能为不希望或禁忌使用ABT的症状性子宫肌瘤女性提供慢性治疗选择。
- 停药后子宫肌瘤相关症状相对快速复发,支持长期继续治疗。
研究设计与样本
- PRIMROSE 1和PRIMROSE 2为基本相同的随机、平行、双盲、安慰剂对照3期试验,纳入子宫肌瘤相关月经过多(每周期月经失血量超过80mL,持续2个月经周期)的女性。
- Full analysis set共纳入1012名女性,随机按1:1:1:1:1分配至安慰剂、linzagolix 100mg单药、linzagolix 100mg联合ABT(1mg雌二醇和0.5mg醋酸炔诺酮)、linzagolix 200mg单药或linzagolix 200mg联合ABT(1mg雌二醇和0.5mg醋酸炔诺酮)。
- 24周后,安慰剂组或linzagolix 200mg单药组患者换用linzagolix 200mg联合ABT,但PRIMROSE 1中50%安慰剂组受试者继续安慰剂至52周;其他女性继续原研究药物。
- 在52周(扩展研究)、64周(停药研究)评估疗效和安全性,76周(停药后6个月)评估骨密度。
主要发现
- 52周时MBL减少的女性比例:100mg组55.0%,100mg联合ABT组86.1%,200mg组/200mg联合ABT组76.7%,200mg联合ABT组89.9%。
- 52周时已达闭经且既往接受linzagolix治疗的受试者中,88.8%在52周至64周之间报告首次出血或大量出血。
- 至52周最常见不良事件为潮热,其发生率至64周恢复至基线值。
- 52周时所有组骨密度保持良好;200mg单药治疗至24周的女性加用ABT后,腰椎骨密度初始丢失至52周恢复。
关键数值与推荐
- 主要终点为MBL降至小于80mL且较基线减少超过50%。
- PRIMROSE1注册号NCT03070899,PRIMROSE 2注册号NCT03070951。
临床怎么用
- 原文未据本研究给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can maintain the efficacy and tolerability seen at 6 months of therapy and whether there is any recurrence of symptoms (bleeding and pain) after cessation of therapy (withdrawal study). DESIGN: PRIMROSE 1 and PRIMROSE 2 were essentially identical, randomized, parallel, double-blind, and placebo-controlled phase 3 trials conducted in women with uterine fibroid-associated heavy menstrual bleeding (HMB) (menstrual blood loss [MBL] of more than 80 mL per cycle over 2 menstrual cycles). SUBJECTS: In PRIMROSE 1 and 2, 1,012 women were included in the full analysis set. Eligible subjects were women aged 18 years or older with ultrasound-confirmed fibroids and HMB of at least 80 mL blood loss per cycle for a minimum of two cycles, as determined by the alkaline hematin method. Eligible participants had to have at least one fibroid measuring 2 cm in diameter or more (or multiple small fibroids with overall uterine volume exceeding 200 cm3), but no fibroids greater than 12 cm in diameter. INTERVENTION: Eligible women with uterine fibroid-associated HMB were randomly assigned at a 1:1:1:1:1 ratio to one of five masked daily treatment: placebo, 100 mg linzagolix alone, 100 mg linzagolix with hormonal ABT (1 mg estradiol and 0.5 mg norethisterone acetate), 200 mg linzagolix alone , or 200 mg linzagolix with hormonal ABT (1 mg estradiol and 0.5 mg norethisterone acetate). After 24 weeks, patients assigned to the placebo or 200 mg linzagolix alone groups were switched to 200 mg linzagolix with ABT, except in PRIMROSE 1, in which 50% of subjects on a placebo continued with the placebo (random selection) until week 52. All other women continued on the original study medication. Efficacy and safety were evaluated at week 52 (extension study) as well as week 64 (withdrawal study). Bone mineral density was also assessed at week 76 (6 months after cessation of therapy). MAIN OUTCOME MEASURES: The primary endpoint was decreased MBL to less than 80 mL and a reduction of more than 50% from baseline. Specifically, this study sought to determine whether the reduction in MBL and other secondary outcomes, such as uterine volume and pain, observed at 24 weeks could be maintained over an extended (52 weeks) treatment period and further withdrawal period. RESULTS: In the pooled data from PRIMROSE 1 and PRIMROSE 2 extension studies, the significantly higher proportion of women showing a reduction in HMB in all linzagolix (with or without ABT) treatment groups observed at week 24, was maintained until week 52. Percentages of women with reduced MBL at week 52 (based on the pooled week 52 full analysis set) were 55.0% in the 100 mg group, 86.1% in the 100 mg with ABT group, 76.7% in the 200 mg group/200 mg with ABT, and 89.9% in the 200 mg with ABT group. Of subjects previously treated with linzagolix and in amenorrhea by week 52, 88.8% reported their first bleed or heavy bleeding between weeks 52 and 64. In both PRIMROSE studies, the most common adverse events up to week 52 were hot flushes. Their incidence had returned to baseline values by week 64. Bone mineral density was well preserved in all groups at week 52. In women treated with 200 mg linzagolix alone up to week 24, initial bone mineral density loss (lumbar spine) recovered by week 52 after adding ABT from week 24 onwards. CONCLUSION: Findings at 52 weeks confirmed the benefits of treatment observed at 24 weeks. At 52 weeks, linzagolix 100 mg or 200 mg with or without ABT was found to reduce HMB, which is a burden for women with uterine fibroids. Their quality of life was improved. Risks of bone loss and vasomotor symptoms were minimized as a result of ABT administration. Partial suppression with once-daily linzagolix 100 mg without ABT potentially provides a unique option for chronic treatment of symptomatic uterine fibroids in women who do not wish to have ABT or in whom it is contraindicated. The relatively fast recurrence of uterine fibroid-associated symptoms after cessation of therapy is an argument in favor of long-term continuation of treatment. TRIAL REGISTRATION: PRIMROSE1 (NCT03070899) PRIMROSE 2 (NCT03070951).
引用
- Donnez J, Petraglia F, Taylor H, et al. Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study. Fertil Steril. 2025. PMID: 40543832. doi:10.1016/j.fertnstert.2025.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。